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Lewy bodies of α-synuclein protein are prominent 
characteristics in the Parkinson’s disease (PD) 
pathology. The mechanism of Lewy body formation 
and consequent cytotoxicity was studied by 
Brandis et al. (2006) in a newly developed model 
organism of fission yeast. Though, the level of α-
synuclein expression studied was either high or 
low, the wild-type and A53T familial mutant of α-
synuclein followed the nucleation polymerization 
theory in the process of misfolding and 
aggregating. At high concentration, α-synuclein 
formed cytoplasmic aggregates in a concentration 
and time-dependent manner. However, these 
aggregates appeared to be independent of 
cytotoxicity. In this current study, the fission yeast 
model is used again but to evaluate α-synuclein 
misfolding, aggregation, and non-toxic properties 
when expression is moderate. The results indicate 
moderate α-synuclein expression to obey the 
nucleation polymerization model. In light of this 
study, α-synuclein aggregation requires a 
necessary threshold concentration. Moderately 
expressed α-synuclein forms soluble aggregates, 
but at a slightly lower expression. So far, studies in 
fission yeast cells show that various 
concentrations of α-synuclein, neither target the 
plasma membrane nor are toxic. Because α-
synuclein misfolding and aggregation is linked to 
Parkinson’s disease, absence of its toxicity in 
fission yeast is paradoxical. We expect that α-
synuclein toxicity may require a membrane binding 
capacity. In an attempt to induce α-synuclein’s 
localization to the plasma membrane, the content of 
phospholipids in yeast was increased. Membrane 
localization and cytotoxicity were still lacking. 
Needless to say, fission yeast shed provocative 




Parkinson’s disease (PD) is the most common 
movement disorder in humans characterized by slowed 
movement, resting tremors, rigidity and postural 
instability. The disabling symptoms of PD result from 
dying midbrain striatal dopaminergic neurons. This 
neurodegenerative disease affects more than 1 million 
Americans over the age of 55 (Collier et al., 2002). 
Sporadic occurrences constitute 95% of all PD cases, 
while genetic occurrences constitute the other 5%. 
There are two well studied familial mutations in the α-
synuclein gene in PD: A30P and A53T. In the disease 
pathology, the reduction of viable neurons correlates 
with the accumulation of misfolded α-synuclein into 
cytoplasmic aggregates called Lewy bodies (Giasson,  
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2001). Numerous model systems in mice (Dauer and 
Przedborski, 2003), worms (Lasko et al., 2003), flies 
(Feany and Bender, 2000) and yeast (Outeiro and 
Muchowski, 2004) have been designed to elucidate α-
synuclein’s biology and the molecular mechanism of 
misfolding, aggregation and cytotoxicity.  
Fission yeast (Schizosaccharomyces pombe) 
is the model organism that our lab (Brandis et al. 2006) 
recently developed to study α-synuclein’s misfolding, 
aggregation, and cytotoxic properties in vivo. The 
advantages of using yeast are that they have a fast life 
cycle and an easy to manipulate genome. Yeast and 
humans have conserved functions in cellular pathways 
such as protein folding, protein degradation, and 
oxidative stress (Wood et al., 2002). When neurological 
diseases strike human beings, one or more of these 
pathways malfunctions. Therefore, yeast can serve as 
an exquisite model for investigating protein misfolding 
neurological disorders. 
The process of Lewy body formation from 
misfolded α-synuclein was first tested in in vitro 
experiments. Studies suggest that α-synuclein 
aggregation follows a hypothetical model called 
nucleation polymerization (Conway et al., 2000). 
Previously, misfolded protein aggregation in many 
neurodegenerative diseases, for instance, beta-
amyloidsin Alzheimer’s Disease, huntingtin in 
Huntington’s Disease, and prion proteins in 
Transmissible Spongiform Encephalopathies was well 
predicted by this model (Caughey and Lansbury, 2003; 
Perutz and Windle, 2001). The nucleation 
polymerization hypothesis states that protein 
aggregation begins with the creation of small oligomer 
(nucleus) seeds. As time and protein concentration 
increases, the oligomers polymerize into polymers 
(aggregates). Thus, the formation of protein aggregates 
is time and concentration dependent.  
Until recently, this hypothesis in PD was 
unsupported by in vivo experiments. However, using 
live fission yeast, Brandis et al. (2006), showed that α-
synuclein aggregates on the basis of the nucleation 
polymerization theory in vivo. In the study, there was 
evidence of large insoluble clumps of α-synuclein 
aggregates which reminds us of the Lewy bodies that 
form in the dying neurons of a Parkinson’s disease 
patient. At high concentration of α-synuclein in fission 
yeast, the aggregates formed in large numbers, but at 
low concentration there were no aggregates. In the 
presence of multiple α-synuclein aggregates, toxicity in 
fission yeast cells was surprisingly absent. Also, the α-
synuclein in fission yeast, in contrast to the other family 
of yeast called budding yeast, never localized to the 
plasma membrane (Brandis et al., 2006).  
On the other hand, research with budding 
yeast has provided key insight into α-synuclein 
misfolding and its ability to disrupt cellular pathways 
leading to cytotoxicity (Outeiro and Muchowski, 2004; 
Cooper et al., 2006). In studies of budding yeast, when 
α-synuclein was expressed at high concentration, it 
formed aggregates with toxic effects (Outeiro and 
Linquist, 2003). In other studies, α-synuclein 
aggregates did not have toxic effects without additional 
genetic knockouts causing proteasomal dysfunction 
(Sharma et al., 2006).        
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Generally, budding yeast and fission yeast 
have inequivalent α-synuclein cellular localizations. In 
budding yeast models, wild-type and A53T mutant α-
synuclein associate with the plasma membrane and 
may form aggregates within the cells. A30P mutant α-
synuclein, on the other hand, remains cytoplasmically 
diffused (Dixon et al., 2005; Outeiro and Lindquist, 
2003; Zabrocki et al., 2005; Sharma et al., 2005). In the 
fission yeast model, we also observe A30P mutant α-
synuclein to be cytoplasmically diffused. However, wild-
type and A53T mutant α-synuclein do not associate 
with the plasma membrane and form cytoplasmic 
aggregates in a time and concentration dependent 
manner (Brandis et al., 2006).  
So far, the nucleation polymerization 
hypothesis can explain why there are more α-synuclein 
aggregates when the protein is expressed in high 
concentration in contrast to when the protein is 
expressed in low concentration (Brandis et al., 2006). In 
light of the nucleation polymerization hypothesis, in the 
first part of this study, we evaluate the expression of 
moderate concentration of α-synuclein in fission yeast. 
At moderate levels of α-synuclein, an intermediate 
number of α-synuclein aggregate formations are 
expected. According to Brandis et al. (2006), these 
aggregates should not influence cytotoxicity.  
In the second part of this study, we examine 
the effect of cellular lipid content on toxicity. Cytotoxicity 
has yet to be observed in fission yeast. In budding 
yeast, cytotoxicity and -synuclein membrane 
localization coexist (Sharma et al., 2006). The 
biochemical property of α-synuclein gives this protein 
the specificity to bind to lipid membranes, inviting the 
question of why is there no α-synuclein dependent 
cytotoxicty in fission yeast (Sharon et al., 2001). It is 
possible that toxicity is contingent on α-synuclein 
membrane localization. Here, we use dimethyl sulfoxide 
(DMSO) to increase the overall lipid content in the 
fission yeast.  In the Murata et al. (2003) study, upon 
exposure to DMSO, there is an induction of membrane 
proliferation in budding yeast. The same induction of 
phospholipid biosynthesis is expected to occur in fission 
yeast. This change in the physiology of fission yeast 
may encourage α-synuclein migration towards the cell 
membranes. According to Volles et al. (2001), 
membranes are the possible locations in the cell where 
α-synuclein can form toxic protofibrils (oligomers). 
These protofibrils can lead to the formation of 
cytoplasmic aggregates (Rochet et al., 2004) or 
possibly toxic cytoplasmic aggregates (Lashuel at al., 
2002). Therefore, we inquire if the α-synuclein’s 
membrane localization is key to cytotoxicity.  
 
Materials and Methods 
 
S. Pombe Expression Vectors 
Human wild-type and A53T mutant α-synuclein cDNAs 
were a gift from Christopher Ross (Johns Hopkins 
University). A30P and A30P/A53T mutant α-synuclein 
were created from wild-type and A53T mutant α-
synuclein, respectively, using site-directed mutagenesis 
(Invitrogen). Polymerase chain reaction (PCR) was 
used to amplify C-terminal green fluorescence protein 
(GFP)-tagged α-synuclein (wild-type, A30P, A53T, 
A30P/A53T) fusion cDNA from the α-sunclein-GFP 
containing pYES2/TOPO S. cerevisiae vectors 
constructed by Sharma et al.(2006): forward primer,   
5’-GGGGCCAAGCTTGCCATGGATGTATTCATGAAA 
GGA-3’; reverse primer, 5’-TTTGTAGAGCTCATACAT 
GCCATG-3’. Similarly, PCR was used to amplify GFP 
cDNA from GFP-pYES/TOPO S. cerevisiae vectors 
constructed by Sharma et al. (2006): forward primer, 
5’CCCGGGACCATGGCCAGCAAAGGAGAAG-3’; 
reverse primer, 5’-TTTGTAGAGCTCATACATGCCA 
TG-3’.  
 These PCR products were subcloned, 
according to the manufacturer’s protocol (Invitrogen), 
into each of these three fission yeast pNMT TOPO-TA 
expression vectors: pNMT1 (for high expression), 
pNMT41 (for intermediate expression), and pNMT81 
(for low expression) vectors. Note that these vectors 
added a V5-epitope and a 6X histidine epitope at the C-
terminal end of the subcloned α-synuclein-GFP 
sequence. These vectors were transformed into 
Escherichia Coli, again according to the manufacturer’s 
protocol (Invitrogen). Positive transformants were 
verified for correctly oriented subcloned cDNA by 
standard bacteria whole-cell PCR. Plasmid vectors 
were purified using a Qiagen miniprep kit, and the 
respective subcloned DNA sequences were confirmed 
(University of Chicago sequencing facility). The parent 
pNMT1, pNMT41, and pNMT81 pREP vectors were 
kindly provided by Judy Potashkin (Rosalind Franklin 
University of Medicine and Science, North Chicago, IL).  
 
Yeast Strains 
The TCP1 strain (h-leu1-32; Invitrogen) of fission yeast 
was kindly provided by Judy Potashkin, Rosalind 
Franklin University of Medicine and Science.  
 
Yeast Transformation 
S. pombe strains were transformed with pNMT vectors 
using the lithium-acetate transformation method (Alfa et 
al., 1993). 
 
Fluorescence Microscopy  
S. pombe cells were first grown overnight at 30oC in 
Edinburgh minimal medium (EMM [Invitrogen]) 
containing thiamine (10µM [to repress α-synuclein 
expression]). After 24h, cells were pelleted at 1500g for 
5 minutes, washed twice in 10ml dH2O, resuspended in 
10 ml EMM without thiamine, of which 125 µL cells 
were used to inoculate 25 mL EMM without thiamine (to 
express α-synuclein). At desired expression time points 
for microscopy, cells were harvested at 1500g (4oC) for 
5 min and were washed in 5 mL water. Then cells were 
resuspended in 100-1000 uL EMM+T, of which 10 uL 
was pipetted onto a slide.  Slide of cell culture was 
viewed using Nikon TE-2000U fluorescence 
microscope at 1000X magnification. Images were 
deconvoluted using MetaMorph software version 4.2. In 
order to quantify α-synuclein aggregates, cells were 
first viewed under differential interference contrast 
(DIC) microscopy, and total cell count in the field was 
determined and viewed for GFP fluorescence. The 
number of cells in the field containing 1, 2, and 3+ 
aggregates was determined. The field was then moved 
three turns on the field control knob, and the process 
was repeated in a new field. At least 750 cells were 
evaluated for each treatment. Aggregates were scored 
as percent of total cells in the field that expressed 1, 2, 
and 3+ aggregates.     
 
Western Analyses 
Yeast cells (2.5x107 cells/ml) were washed in 50 mM 
Tris (pH 7.5), 10 mM NaN3 and solubilized in 
Electrophoresis Sample Buffer (ESB; Burke, 2000) 
containing 2% sodium dodecyl sulfate (SDS), 80 mM 
Tris (Ph 6.8), 10% glycerol, 1.5% dithiothreitol, 1 mg/ml 
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bromophenol blue, and a cocktail of protease inhibitors 
and solubilizing agents (1% Triton-X 100, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 
mM sodium orthovanadate, 0.7 µg/ml pepstatin A, 0.5 
µg/ml leupeptin, 10 µg/ml E64, 2µg/ml aprotinin, and 2 
µg/ml chymostatin).   Samples were run on pre-cast 10-
20% Tris-Glycine gels (Invitrogen) using SDS 
containing running buffer. SeeBlue (Invitrogen) was 
used as the molecular standard. Gels were transferred 
to PVDF membranes and Western blot was performed 
with anti-V5 AP monoclonal antibody using standard 




Cells were grown in 10 ml EMM+T overnight at 30°C in 
the incubator which rotates at 200 rpm. Cells were 
harvested at 1500 x g for 5 min at 4°C, and were 
washed twice in 5 ml H20. Cells were re-suspended in 5 
ml H20 and were counted. Flasks with 25 ml EMM were 
each inoculated with 2.0x106cells/ml density. At 0, 6, 
12, 18, 24, and 36 hours, and in duplicate 
measurements, 1 ml of cell culture was removed and 
placed in a cuvet to measure absorbance using a 
Hitachi U-2000 Spectrophotometer. Averaged 
absorbance readings were plotted against time points 
to produce a growth curve.  
 
DMSO Treatment 
Dimethyl sulfoxide (DMSO) was purchased from 
Sigma-Aldrich. Cells were grown in 10 ml EMM+T 
overnight at 30°C. Steps of cell harvesting and 
calculating cell density for inoculation was done 
according to the appropriate experiment. The cells had 
high expressing α-synuclein pNMT-1 vectors. Before 
inoculation, DMSO was added in the range of 0 to 10% 
in EMM media. The concentration of DMSO exposure 
was increased only up to 10%, technically exceeding 
this percent of DMSO would do harm to the cell 
(Zabrocki et al., 2005). After the DMSO mixed well in 
the media, yeast cells were inoculated, and grown. 
Then the cells were observed at the desired time points 
for the following examinations: Growth Curves and 




Moderately Expressed α-Synuclein Aggregates in Live 
Cells 
α-synuclein localization in fission yeast is screened as 
the expression of the protein, promoted by pNMT-41 
vector, is in moderate concentration. Fluorescence 
microscopy indicates A30P, A53T, and A30P/A53T 
mutant α-synuclein localizations. The protein 
expression level is slightly higher than the expression 
by pNMT-81 vector (refer to Figure 5C: Western 
Analysis in Brandis et al., 2006). A53T α-synuclein 
forms cytoplasmic aggregates. Meanwhile, A30P and 
A30P/A53T α-synuclein remain cytoplasmically 
diffused. Even in this moderate concentration, 
α−synuclein never localizes to the plasma membrane. 
These expression characteristics from all isoforms of α-
synuclein in live fission yeast match previous findings 
(Brandis et. al, 2006) (Figure 1). 
Figure 1. Fluorescence Microscopy of pNMT-41 Medium Expression: α-Synuclein was expressed in moderate concentration by 
pNMT41 promoter vector. These yeast were grown in EMM without thiamine. Images were captured at the indicated times over 36 hours.  
A53T α-synuclein began to form aggregates at the 18th hour time point.  A30P and A30P/A53T exhibited diffuse cytoplasmic fluorescence 
throughout the time course. 
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Quantification of Moderately Expressed α-Synuclein 
Aggregates 
Quantifying the aggregates for A53T mutant α-
synuclein is necessary to make qualitative assessment 
on how these aggregates form. At moderate 
concentrations of α-synuclein, nucleation 
polymerization hypothesis predicts a delayed formation 
of an intermediate number of aggregates. The data 
showed that formation of aggregates was time-
dependent, as they started appearing at the 18th hour 
(Figure 2A). Additionally, when compared to Brandis et 





the nucleation polymerization theory. First, the time of 
formation of aggregates at moderate concentration was 
six hours later when compared to the time of aggregate 
formation at high concentration. Second, throughout the 
36 hour time course, the percent of cells forming 
aggregates were lower for moderate concentration 
compared to high concentration (Figure 2B).  
 
Toxicity Levels of Moderately Expressed α-Synuclein 
Aggregates 
Brandis et al. (2006) suggest that even at high 
concentrations of α-synuclein leading to formation of 
many aggregates, the cytotoxicity levels were minimal. 
An optical density assay performed in this study 
showed no toxicity in the cells expressing α-synuclein 
in moderate concentration either (Figure 3). The control 
in this growth analysis was a culture of parent vector 
(pNMT-41) cells that did not express α-synuclein. None 
of the isoforms of α-synuclein was toxic to fission yeast 
(Figure 3). Next, we investigated whether membrane 
localization was critical for toxicity. The lipid content of 
fission yeast cells was induced to promote α-synuclein 













Is α-Synuclein Membrane Localization Gained With 
Exposure to DMSO? 
Contrary to the prediction, upon DMSO exposure to 
fission yeast cells, no α-synuclein lipid binding property 
was observed. α-Synuclein aggregates did not 
decrease also. The aggregation inducing property of Wt 
(Figure 4) and A53T and as well as the cytoplasmically 
Figure 2B. Comparison of moderate to high expression 
of quantified A53T α-synuclein aggregation.  
Comparison of quantified data on A53T α-synuclein 
aggregates with high expression (red bar) (Quantification 
data provided by Brandis et al. 2006) compared to 
moderate expression (green bar) over the 36-hr period. 
Bars represent percentage of total cells that had 1 or more 
aggregates per cell. 
Figure 2A. Time course of quantified A53T α-synuclein 
aggregation. Cells, cultured in EMM media without 
thiamine, expressed α-synuclein in moderate 
concentrations. The number of aggregates formed was 
quantized in cells expressing A53T α-synuclein over a 36-
hr time course. Cells were scored in terms of containing 1 
aggregate (blue bar), 2 aggregates (yellow bar), or 3 or 
more aggregates (red bar). Bars represent percentage of 
total cells counted in each sample that exhibited the 
designated number of aggregates per cell.  
 
Figure 3. Growth Curve of Cells Moderately Expressing 
α-Synuclein. OD600 measurements were obtained over 
48 hours for cells containing A30P, A53T, and A30/A53T 
forms of α-synuclein that were tagged with GFP in 
pNMT41 vector. Cells grown in thiamine (dashed lines) 
served as control. Concentration-dependent α-synuclein 








diffused property of A30P and A30P/A53T were 
unchanged in exposure to DMSO (data not shown). 
These observations were made under fluorescence 
microscopy. 
        
Are Toxicity Levels Enhanced in Fission Yeast with 
Exposure to DMSO? 
All fission yeast in varying concentrations of DMSO 
showed a slight inhibition in their growth. We 
considered this result anomalous because 0% DMSO 
particularly should not be toxic. It contradicts the 
findings by Brandis et al. (2006). In turn, we tried to 
clarify the inconsistencies by rerunning the DMSO 
treatment experiment (Figure 5).  
In the second trial, cells were treated with 0 %, and 4.5 
% DMSO. This time, the control group with no exposure 
to DMSO had normal growth. As the DMSO exposure 
climbs to 4.5%, toxicity was not observed. Under toxic 
conditions, there would have been a lag in the growth 
curves (Figure 6). 
Yet, these two trials’ results were 
contradictory. In exposure to DMSO, the first trial 
Figure 4.  Fluorescence Microscopy of pNMT-1 High expression Cells Exposed to DMSO: Cells were grown in EMM media without 
thiamine, expressing α-synuclein in high concentration promoted by pNMT-1 vector. Florescence microscopy cell images were captured at 
the 24th hour.  Wt α-synuclein did not gain membrane localization and the cytoplasmic aggregates still remain in fission yeast with exposure 
to varying concentrations of DMSO.  
 
Figure 5. Growth Curve Analysis on α-Synuclein Expressing cells Exposed to DMSO (1st Trial): OD600 measurements over 48 
hours were obtained for cells that express α-synuclein in high concentration. Control cells had simply GFP or parent-plasmid. Cells 
were grown in EMM media without thiamine. The growth was measured in exposure to different amounts (0%, 2%, and 10%) of 
DMSO. The data showed slight inhibition in growth. 
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showed slight inhibition of cellular growth, while the 
second trial showed normal growth. In the future, 
several more trials of DMSO treatment on α-synuclein 
expressing fission yeast are necessary.   
   
Discussion 
 
From the past study by Brandis et al. (2006) and this 
current study, we have successfully developed fission 
yeast as a model organism to study the misfolding, 
aggregation, and cytotoxic properties of α-synuclein 
linked to Parkinson’s disease. Specifically, work with 
fission yeast sheds provocative insight into the ideas 
that concentration of α-synuclein is important for the 
protein’s aggregation and α-synuclein membrane 
localization might be critical for the protein dependent 
toxicity.  
 
α-Synuclein aggregation: concentration is key 
The protein’s polymerization activity is concentration 
dependent. At high concentrations, there are many α-
synuclein aggregates, while at low concentrations there 
are no α-synuclein aggregates (Brandis et al, 2006). In 
the current study, at moderate concentration, α-
synuclein forms an intermediate number of aggregates. 
According to data by Brandis et al. (2006), the protein 
expression of moderate concentration was only slightly 
higher than the protein expression of the low 
concentration. Conversely, the low concentration of α-
synuclein was not enough to lead to the formation of 
insoluble aggregates. Therefore, the evidence indicates 
that slightly higher (moderate) concentration of α-
synuclein is required to form aggregates. We consider 
the moderate concentration or a concentration near to it 
as the threshold point of α-synuclein protein 
concentration that must be present to turn the soluble 
protein into insoluble aggregates. As protein 
concentration increases, the oligomers polymerize to 
form greater numbers of aggregates. Moreover, α-
synuclein aggregation activity is time-dependent. 
Overall, Brandis et al. (2006) and this study display 
both concentration and time-dependent α-synuclein 
aggregation properties which support the grounds for 
the nucleation polymerization model in vivo. 
 
Toxicity: is membrane localization key?                            
To this date, in a fission yeast model, membrane 
localization has not been observed with cytotoxicity. In 
the budding yeast model, there is evidence of 
membrane localization with toxicity (Sharma et al., 
2006). This leads to the hypothesis that membrane 
localization might be key to cytotoxicity.  We did not 
observe α-synuclein dependent toxicity in fission yeast, 
but we still suspect that toxicity requires α-synuclein 
membrane localization. In a previous study by Rochet 
et al. (2004), membrane localization of α-synuclein was 
shown to be essential in creating toxic protofibrils. 
Under a different study, the destruction of vesicular 
membranes by protofibrillar α-synuclein was directly 
observed by atomic force microscopy (Volles et al., 
2001). In our lab, the toxicity of budding yeast was 
observed when α-synuclein localized at the cell 
periphery. In budding yeast, the localization of α-
synuclein to the plasma membrane happened prior to 
the formation of α-synuclein aggregates. With the 
exception of A30P, wild-type and A53T α-synuclein 
localized to the plasma membrane before forming 
inclusions (Sharma et al., 2006). Conversely, in our 
fission yeast model, neither toxicity nor membrane 
association was observed. Overall, a connection 
between α-synuclein-dependent toxicity and α-




To more conclusively elucidate α-synuclein’s 
membrane association and yeast toxicity, the 
approaches of treating fission yeast with DMSO must 
be refined and repeated. Further research is crucial 
because several yeast models already suggest that 
membrane localization of α-synuclein is critical to 
pathogenesis (Dixon et al., 2005; Outeiro and Lindquist, 
2003; Zabrocki et al., 2005). 
 Additionally, this future investigation can be 
done in budding yeast by reducing the lipid 
concentration of the membrane and then measuring 
changes in α-synuclein toxicity. Cho1 and Cho2 are 
knockouts in budding yeast strain W303 that code for 
enzymes critical to making major cell membrane 
phospholipids. Cho 1 encodes for phosphatidylserine 
synthase enzyme that coverts CDP-DG, a precursor to 
two of the major phospholipids in the membranes 
namely PI and PS. Cho 2 encodes a PL methyl 
transferase to produce PC from PE phospholipids. 
Using knockouts of these genes, budding yeast can be 
manipulated to give lipid deficient cells (Carman and 
Zeimetz, 1996). α-Synuclein must have specificity for 
binding to one of the major phospholipids. The 
Figure 6. Growth Curve Analysis on α-Synuclein Expressing cells Exposed to DMSO (2nd Trial): OD600 measurements over 48 
hours were obtained for cells that express α-synuclein in high concentration. Control cells had simply GFP or parent-plasmid. Cells 
were grown in EMM media without thiamine. The growth was measured in exposure to different amounts (0%, 4.5%) of DMSO. The 
control growth curves with no DMSO exposure had normal s-shaped curves. DMSO exposure of 4.5% did not cause toxic effects.    
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knockout of one or more of the major membrane 
phospholipids may advance the loss of α-synuclein 
membrane localization. If this loss occurs, we predict 
the reduction in toxicity levels.  
 We observed the formation of α-synuclein 
aggregates in fission yeast that did not acquire the 
initial membrane localization. This step may have been 
essential to creating toxic protofibrils and/or toxic 
cellular aggregates. We predict that the budding and 
fission yeast models will facilitate the establishment of 
α-synuclein association with the membrane 
phospholipids as a necessary characteristic to increase 
cytotoxicity levels. α-Synuclein is an abundant and 
broadly expressed protein in the human brain, where it 
interacts with membranes and vesicular structures 
(Outeiro and Lindquist, 2003). The α-synuclein property 
of associating with membranes and its link to 
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